Literature DB >> 9703288

Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.

N Masuda1, S Negoro, K Takeda, N Kurata, T Kuwabara, S Kobayashi, M Fukuoka.   

Abstract

The precise mechanism of fever and flu-like syndrome that occurs in treatment with deoxycytidine analogues remains unclear. This study demonstrated a strong correlation between plasma interleukin 6 levels and fever in treatment with oral (E)-2'-deoxy-2'(fluoromethylene)cytidine, another deoxycytidine analogue.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9703288      PMCID： PMC2063033          DOI： 10.1038/bjc.1998.504

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  6 in total

1.  Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.

Authors:  T J O'Rourke; T D Brown; K Havlin; J G Kuhn; J B Craig; H A Burris; W G Satterlee; P G Tarassoff; D D Von Hoff
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

2.  Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

Authors:  H Anderson; B Lund; F Bach; N Thatcher; J Walling; H H Hansen
Journal:  J Clin Oncol       Date:  1994-09       Impact factor: 44.544

3.  Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

Authors:  R P Abratt; W R Bezwoda; G Falkson; L Goedhals; D Hacking; T A Rugg
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

4.  Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.

Authors:  E A Poplin; T Corbett; L Flaherty; P Tarasoff; B G Redman; M Valdivieso; L Baker
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

5.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Authors:  J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

6.  A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.

Authors:  H Anderson; N Thatcher; J Walling; H Hansen
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.